All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Martin DreylingDuring the 17th International Conference on Malignant Lymphomas (17-ICML), the Lymphoma Hub spoke with Martin Dreyling, Ludwig-Maximilians-Universität, Munich, DE. We asked, What are the take-home messages from 17-ICML?
What are the take-home messages from 17-ICML?
Dreyling explains that Hodgkin's lymphoma was an important theme of the conference this year, he discusses:
- The SWOG 1826 trial of finding nivolumab in combination with chemotherapy, which could be a new standard-of-care treatment for patients with relapsed/refractory Hodgkin’s lymphoma.
- The HD21 trial results concluding BrECADD has less treatment-related morbidities than eBEACOPP.
- Immunotherapy being considered as standard-of-care treatment for patients with aggressive lymphoma after from results of the ZUMA-7 trial; chimeric antigen receptor T-cell therapy is more successful as a second-line therapy than third-line.
- The EPCORE DLBCL-2 study summarizing epcoritimab + R-CHOP is feasible in patients as first-line treatment of DLBCL.
Drelying concludes that immunotherapy may challenge standard-of-care R-CHOP treatment in the first-line of treatment of DLBCL.
Your opinion matters
Which of the following do you consider a key challenge when implementing the BrECADD regimen for the treatment of Hodgkin lymphoma?